Edge
StocktwitsEarnings

Official STOCKTWITS Representative

$RGNX Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.43 up 131.16% YoY
• Reported revenue of $108.02M up 405.73% YoY
• REGENXBIO expects its balance in cash, cash equivalents, and marketable securities as of June 30, 2026, plus July 2026 proceeds, are sufficient to fund operations for REGENXBIO into Q4 2027.Price since post
Advertisement|Remove ads.